Page last updated: 2024-12-05

indolepropionic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Indolepropionic acid (IPA) is a naturally occurring compound found in various plants and animals. It is a derivative of the amino acid tryptophan and is produced through the breakdown of tryptophan in the gut by bacteria. IPA has been shown to exhibit a range of biological effects, including anti-inflammatory, antioxidant, and neuroprotective properties. It has also been investigated for its potential therapeutic applications in conditions such as inflammatory bowel disease (IBD), cancer, and neurodegenerative disorders. IPA's anti-inflammatory properties are attributed to its ability to inhibit the production of pro-inflammatory cytokines, such as TNF-alpha and IL-6. Furthermore, IPA has shown promise in reducing oxidative stress and protecting cells from damage. The mechanisms underlying IPA's beneficial effects are still under investigation, but studies suggest that it may act through multiple pathways, including modulation of the gut microbiota, activation of the Nrf2 pathway, and inhibition of the NF-κB signaling pathway. The potential therapeutic applications of IPA have led to increased research efforts in recent years, with several studies focusing on its effectiveness in various disease models. IPA's ability to modulate the gut microbiota, its anti-inflammatory and antioxidant properties, and its neuroprotective effects make it a promising therapeutic candidate for a range of conditions. However, further research is required to fully understand its mechanisms of action, optimize its delivery, and determine its safety and efficacy in humans.'

indolepropionic acid: structure in third source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

3-(1H-indol-3-yl)propanoic acid : An indol-3-yl carboxylic acid that is propionic acid substituted by a 1H-indol-3-yl group at position 3. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID3744
CHEMBL ID207225
CHEBI ID43580
SCHEMBL ID195405
SCHEMBL ID1767754
MeSH IDM0064447

Synonyms (118)

Synonym
BIDD:GT0788
indole-3-propionic
indole-3-propanoic acid
unii-jf49u1q7kn
vp 20629
jf49u1q7kn ,
5-22-03-00114 (beilstein handbook reference)
3-(3-indolyl)propionic acid
3-(2-carboxyethyl)-1h-indole
1h-indole-3-propanoic acid
1h-indole-3-propionic acid
.beta.-indolepropionic acid
.beta.-(3-indolyl)propionic acid
ipa (auxin)
nsc-3252
3-(3-indolyl)propanoic acid
830-96-6
nsc3252
.beta.-indole-3-propionic acid
indole-3-propionic acid
.beta.-indolylpropionate
3-(3-indole)propionic acid
nsc-47831
nsc47831
DIVK1C_001183
oxigon
vp-20629
SDCCGMLS-0065895.P001
nsc 3252
ccris 4424
beta-(3-indolyl)propionic acid
1h-indole-3-proponoic acid
einecs 212-600-1
nsc 47831
ai3-17433
brn 0147733
CDS1_000143
3-indolepropionic acid ,
3-(1h-indol-3-yl)propanoic acid
OPREA1_071255
indolylpropionic acid
inchi=1/c11h11no2/c13-11(14)6-5-8-7-12-10-4-2-1-3-9(8)10/h1-4,7,12h,5-6h2,(h,13,14
3-(indol-3-yl)propionic acid
beta-indolylpropionate
DB02758
indolepropionic acid
3-indolepropionic acid, reagentplus(r), 99%
MAYBRIDGE1_002431
I-4000
STK247053
indole-3-propionic acid, >=99.0% (t)
indole-3-propionic acid, >=97.0% (t)
bdbm31879
acid, 7
AC-10570
HMS548G11
3-indolepropionicacid
chebi:43580 ,
CHEMBL207225
I0032
AKOS000120911
BBL001406
3-(1h-indol-3-yl)-propionic acid
CCG-115418
FT-0627221
FS-3158
AM20060737
4EJL
S4809
gtpl4709
BP-21044
AB01333057-02
3-indolpropionic acid
3-(1h-indol-3-yl)propionic acid
3-(3-indolyl)-propionic acid
3-indole propionic acid
indole-3-proprionic acid
SCHEMBL195405
shp622
shp-622
vp20629
SCHEMBL1767754
DTXSID7061192
SY015400
mfcd00005660
J-650104
3-(1h-indol-3-yl)propanoic acid #
HMS3604I20
F0849-0388
b-indolepropionic acid
beta-indole-3-propionate
beta-indolepropionate
beta-indolepropionic acid
3-indolepropionate
beta-indole-3-propionic acid
3-(3-indolyl)propanoate
b-(3-indolyl)propionate
b-indole-3-propionic acid
3-(3-indolyl)propionate
b-indolepropionate
b-indole-3-propionate
beta-(3-indolyl)propionate
b-(3-indolyl)propionic acid
1h-indole-3-propionate
3-indolepropionic acid, vetec(tm) reagent grade, 99%
HY-W015229
CS-W015945
NCGC00340705-01
3-indolepropenoic acid
3-(indol-3-yl)propanoic acid
10265-77-7
BCP26573
Q21098993
HMS3886E03
C22236
trihy(droxymethyl)aminomethane
EN300-20789
Z104482518

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" Owing to the potential pitfalls of FMT, IPA might be employed as a safe and effective succedaneum to fight against accidental or iatrogenic ionizing ARS in clinical settings."( Gut microbiota-derived indole 3-propionic acid protects against radiation toxicity via retaining acyl-CoA-binding protein.
Cui, M; Dong, JL; Fan, SJ; Jiang, M; Li, Y; Wang, B; Wang, HC; Xiao, HW; Zhang, SQ; Zhu, CC; Zhu, T, 2020
)
0.56

Bioavailability

ExcerptReferenceRelevance
" The findings demonstrated herein therefore strongly suggest that the amphiphilic character enhances the bioavailability of the antioxidants and allows for a selective targeting of mitochondria."( Fluorinated amphiphilic amino acid derivatives as antioxidant carriers: a new class of protective agents.
Böker, J; Durand, G; Hardeland, R; Ortial, S; Pappolla, MA; Poeggeler, B; Polidori, A; Pucci, B, 2006
)
0.33

Dosage Studied

ExcerptRelevanceReference
" The experimental cohorts were dosed for four consecutive weeks with aflatoxin B1 (50 μg/kg), 3-indolepropionic acid (50 mg/kg), and both (aflatoxin B1: 50 μg/kg + 3-indolepropionic acid: 25 or 50 mg/kg), and the untreated control."( Decrease in reproductive dysfunction using aflatoxin B1 exposure: a treatment with 3-indolepropionic acid in albino Wistar rat.
Najophe, ES; Otunla, MT; Owumi, SE; Oyelere, AK, 2022
)
1.16
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
auxinAny of a group of compounds, both naturally occurring and synthetic, that induce cell elongation in plant stems (from Greek alphaupsilonxialphanuomega, "to grow").
human metaboliteAny mammalian metabolite produced during a metabolic reaction in humans (Homo sapiens).
plant metaboliteAny eukaryotic metabolite produced during a metabolic reaction in plants, the kingdom that include flowering plants, conifers and other gymnosperms.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
indol-3-yl carboxylic acidAny indolyl carboxylic acid carrying an indol-3-yl or substituted indol-3-yl group.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
Tryptophan metabolism2342

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (4)

Processvia Protein(s)Taxonomy
biosynthetic processKynurenine--oxoglutarate transaminase 1Homo sapiens (human)
response to bacteriumKynurenine--oxoglutarate transaminase 1Homo sapiens (human)
kynurenine metabolic processKynurenine--oxoglutarate transaminase 1Homo sapiens (human)
L-kynurenine catabolic processKynurenine--oxoglutarate transaminase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (6)

Processvia Protein(s)Taxonomy
protein bindingKynurenine--oxoglutarate transaminase 1Homo sapiens (human)
kynurenine-oxoglutarate transaminase activityKynurenine--oxoglutarate transaminase 1Homo sapiens (human)
pyridoxal phosphate bindingKynurenine--oxoglutarate transaminase 1Homo sapiens (human)
protein homodimerization activityKynurenine--oxoglutarate transaminase 1Homo sapiens (human)
glutamine-phenylpyruvate transaminase activityKynurenine--oxoglutarate transaminase 1Homo sapiens (human)
cysteine-S-conjugate beta-lyase activityKynurenine--oxoglutarate transaminase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (3)

Processvia Protein(s)Taxonomy
cytosolKynurenine--oxoglutarate transaminase 1Homo sapiens (human)
cytoplasmKynurenine--oxoglutarate transaminase 1Homo sapiens (human)
mitochondrionKynurenine--oxoglutarate transaminase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (18)

Assay IDTitleYearJournalArticle
AID288184Permeability coefficient through artificial membrane in presence of unstirred water layer by PAMPA2007Bioorganic & medicinal chemistry, Jun-01, Volume: 15, Issue:11
QSAR study on permeability of hydrophobic compounds with artificial membranes.
AID264479Lipophilicity, log k'w of the compound2006Journal of medicinal chemistry, May-04, Volume: 49, Issue:9
Fluorinated amphiphilic amino acid derivatives as antioxidant carriers: a new class of protective agents.
AID264481Radical reducing potency by ABTS cation radical reduction assay per 30 mins at 1 umol/mL2006Journal of medicinal chemistry, May-04, Volume: 49, Issue:9
Fluorinated amphiphilic amino acid derivatives as antioxidant carriers: a new class of protective agents.
AID264480Hydroxyl radical scavenging activity by ABTS competition assay per 30 mins at 1 umol/mL2006Journal of medicinal chemistry, May-04, Volume: 49, Issue:9
Fluorinated amphiphilic amino acid derivatives as antioxidant carriers: a new class of protective agents.
AID1604348Antitubercular activity against Mycobacterium tuberculosis H37Rv ATCC 27294 after 10 days2019Bioorganic & medicinal chemistry letters, 12-01, Volume: 29, Issue:23
Mycobacterial tryptophan biosynthesis: A promising target for tuberculosis drug development?
AID288192Partition coefficient, log P of the compound2007Bioorganic & medicinal chemistry, Jun-01, Volume: 15, Issue:11
QSAR study on permeability of hydrophobic compounds with artificial membranes.
AID264484Inhibition of doxorubicin-induced death of mixed cortical cells of E15 Sprague-Dawley rat embryo at 10 uM2006Journal of medicinal chemistry, May-04, Volume: 49, Issue:9
Fluorinated amphiphilic amino acid derivatives as antioxidant carriers: a new class of protective agents.
AID349604Inhibition of human recombinant KAT1 expressed in Sf9 cells2009Journal of medicinal chemistry, May-14, Volume: 52, Issue:9
Structural insight into the inhibition of human kynurenine aminotransferase I/glutamine transaminase K.
AID1604349Cytotoxicity against human HepG2 cells after 24 hrs by CellTiter 96 AQueous One Solution Cell Proliferation assay2019Bioorganic & medicinal chemistry letters, 12-01, Volume: 29, Issue:23
Mycobacterial tryptophan biosynthesis: A promising target for tuberculosis drug development?
AID439612Antagonist activity at human T1R2/T1R3 receptor expressed in HEK293E cells assessed as inhibition of sucralose-induced intracellular calcium mobilization2009Journal of medicinal chemistry, Nov-12, Volume: 52, Issue:21
Phenoxy herbicides and fibrates potently inhibit the human chemosensory receptor subunit T1R3.
AID264485Viability of rotifers against hydrogen peroxide toxicity at 10 uM2006Journal of medicinal chemistry, May-04, Volume: 49, Issue:9
Fluorinated amphiphilic amino acid derivatives as antioxidant carriers: a new class of protective agents.
AID1604351Antitubercular activity against Mycobacterium tuberculosis H37Rv infected in BALB/c mouse assessed as reduction in bacterial load in infected mouse spleen at 100 mg/kg, po administered 6 days per week for 4 weeks relative to control2019Bioorganic & medicinal chemistry letters, 12-01, Volume: 29, Issue:23
Mycobacterial tryptophan biosynthesis: A promising target for tuberculosis drug development?
AID1604350Oral bioavailability in CD-1 mouse at 100 mg/kg measured up to 24 hrs2019Bioorganic & medicinal chemistry letters, 12-01, Volume: 29, Issue:23
Mycobacterial tryptophan biosynthesis: A promising target for tuberculosis drug development?
AID264482Inhibition of hydrogen peroxide-induced death of mixed cortical cells of E15 Sprague-Dawley rat embryo at 10 uM2006Journal of medicinal chemistry, May-04, Volume: 49, Issue:9
Fluorinated amphiphilic amino acid derivatives as antioxidant carriers: a new class of protective agents.
AID264486Viability of rotifers against doxorubicin toxicity at 10 uM2006Journal of medicinal chemistry, May-04, Volume: 49, Issue:9
Fluorinated amphiphilic amino acid derivatives as antioxidant carriers: a new class of protective agents.
AID264483Inhibition of peroxynitrite-induced death of mixed cortical cells of E15 Sprague-Dawley rat embryo at 10 uM2006Journal of medicinal chemistry, May-04, Volume: 49, Issue:9
Fluorinated amphiphilic amino acid derivatives as antioxidant carriers: a new class of protective agents.
AID977611Experimentally measured binding affinity data (Kd) for protein-ligand complexes derived from PDB2013ACS chemical biology, , Volume: 8, Issue:6
Small molecule regulation of protein conformation by binding in the Flap of HIV protease.
AID1799182hKAT-I Activity Assay from Article 10.1021/jm9000874: \\Structural insight into the inhibition of human kynurenine aminotransferase I/glutamine transaminase K.\\2009Journal of medicinal chemistry, May-14, Volume: 52, Issue:9
Structural insight into the inhibition of human kynurenine aminotransferase I/glutamine transaminase K.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (101)

TimeframeStudies, This Drug (%)All Drugs %
pre-199015 (14.85)18.7374
1990's13 (12.87)18.2507
2000's25 (24.75)29.6817
2010's27 (26.73)24.3611
2020's21 (20.79)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 42.05

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index42.05 (24.57)
Research Supply Index4.65 (2.92)
Research Growth Index4.82 (4.65)
Search Engine Demand Index59.27 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (42.05)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (0.97%)5.53%
Reviews5 (4.85%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other97 (94.17%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]